Medical
Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains as CDC reports
possible mutations in bird flu
Investorideas.com (www.investorideas.com) a go-to platform for
big investing ideas for stock traders, including biotech and medical tech stocks reports on trading and
news for Aethlon
Medical, Inc.
(Nasdaq: AEMD), a medical therapeutic company focused on
developing products to treat cancer and life-threatening infectious diseases.
Aethlon is trading up today on investor speculation
of bird flu stocks, currently trading at $0.7500, up 0.0893, gaining 13.6107%
on volume of over 2.6 Million shares as of this report.
According to Sciencealert.com today, “The
ongoing spread of bird flu in the United States has alarmed experts – not just
because of human cases causing severe illness, but also due to troubling new
instances of infections in cats.”
“A sample of the virus found in a critically ill
patient in the United States has shown signs of mutating to better suit human
airways, although there is no indication it has spread beyond that individual,
authorities report.”
“Earlier this month, officials announced that an
elderly Louisiana patient was in "critical condition" with a severe
H5N1 infection. “
On December 20th, Aethlon
Medical, Inc. (NASDAQ: AEMD) provided a statement of its investigational medical
device with respect to H5N1 avian influenza "Bird Flu."
Aethlon has recently received a number of inquiries
regarding the potential utility of its Hemopurifier device in the treatment of
Bird Flu. These inquiries come on the heels of the reporting of isolation of
Bird Flu in dairy cows, 60 human cases in eight states including a case of
severe infection in Louisiana, and yesterday's declaration of a state of
emergency in California.
Paid news dissemination for Aethlon
Medical.
Read this news,
featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/12311Medical-Therapeutic-Stock-AEMD.asp
The Aethlon Hemopurifier is an investigational
extracorporeal medical device designed to remove enveloped viruses and
extracellular vesicles from the bloodstream. The device incorporates plasma
separation, size exclusion, and affinity binding to a proprietary resin
containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a
medical grade diatomaceous earth. Enveloped viruses and extracellular vesicles
contain the sugar mannose on their surface, which is the therapeutic target of
the GNA.
Aethlon has previously contracted Battelle labs to examine
the in vitro removal of influenza viruses including H5N1 by a scaled down
version of the Aethlon Hemopurifier. In this experiment, cell culture media was
spiked with the H5N1 virus and continuously circulated over the device. Samples
were taken periodically to examine viral removal by the device. In this study,
a miniature version of the device removed 99% of H5N1 following 6 hours of
treatment.
While the Aethlon Hemopurifier has not yet been used to
treat patients with severe influenza, including those infected with H5N1, it
has been used in 38 patients across 164 distinct treatment sessions, targeting
diseases such as hepatitis C, HIV, and in patients critically ill due to
COVID-19 and Ebola. The Hemopurifier has a "breakthrough device"
designation with the FDA for life-threatening viruses for which there is no
effective treatment.
Recent news release
https://www.investorideas.com/news/2024/12201AEMD-Hemopurifier-H5N1-Bird-Flu.asp
Biotech stocks
to watch:
Research more Biotech and medical technology
stocks with Investorideas.com free stock directory
About Investorideas.com - Big
Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From
breaking stock news to top-rated investing podcasts, we cover it all. Our
original branded content includes podcasts such as Exploring Mining, Cleantech,
Crypto Corner, Cannabis News, and the AI Eye. We also create free investor
stock directories for sectors including mining, crypto, renewable energy,
gaming, biotech, tech, sports and more. Public companies within the sectors we
cover can use our news publishing and content creation services to help tell
their story to interested investors.
Disclaimer/Disclosure: This
news alert for AEMD is part of Investorideas.com paid
content on behalf of Aethlon Medical. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more.. Contact management and IR of
each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, IR, PR and
social media, podcast sponsorship and ticker tag content creation services at
Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about digital advertising
and guest posts/sponsored posts
https://www.investorideas.com/Advertise/
Follow us on X @investorideas @stocknewsbites
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Sign up for free
stock news alerts at Investorideas.com
Contact
Investorideas.com
800 665 0411
Biotech Industry Stocks-
investing ideas in biotechnology stocks, medical technology and life sciences
Get more biotech and medical tech
news, articles, podcasts
and stock directories
No comments:
Post a Comment